KR
Krsnaa Diagnostics Ltd (KRSNAA)
₹519.05
Mkt cap
₹1,684 Cr
P/E ratio
16.70
P/B
1.60
Div yield
0.39%
ROE
10.90%
ROCE
12.70%
EPS (TTM)
₹31.08
Book value
₹324
52W range
463–838
Sector
Healthcare
Price history
Previous close
Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns. [1]
NSE KRSNAABSE 543328
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthHigh
TechnicalsBearish
52-week range
−38.06% from high₹519
₹463+12.08% from low₹838
Current
₹519.05
Prev close
₹515.65
Day
+0.66%
Price performance
1D
+0.80%
1W
−1.69%
1M
+0.80%
3M
−5.49%
6M
−7.49%
1Y
−35.52%
YTD
−29.22%
Financials
Revenue, profit & margin
P/E ratio
16.7×
KRSNAA is 52% below the sector median of 35.0×
KRSNAA16.7×
Sector median35.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 147 | 152 | 159 | 163 | 179 | 165 | 175 | 176 | 183 | 159 | 173 | 211 | 240 | |
| YoY Sales growth | +22% | +31% | +38% | +23% | +22% | +9% | +10% | +8% | +2% | -3% | -1% | +20% | +31% | |
| Expenses | 116 | 113 | 116 | 120 | 126 | 117 | 121 | 126 | 125 | 112 | 116 | 154 | 168 | |
| Operating Profit | 31 | 38 | 43 | 43 | 52 | 48 | 53 | 50 | 58 | 48 | 57 | 57 | 72 | |
| OPM % | 21% | 25% | 27% | 26% | 29% | 29% | 31% | 29% | 32% | 30% | 33% | 27% | 30% | |
| Other Income | 4 | 4 | 4 | 7 | 5 | 9 | 4 | 4 | 4 | 4 | 31 | 7 | 6 | |
| Interest | 3 | 4 | 7 | 5 | 6 | 6 | 7 | 6 | 8 | 8 | 12 | 15 | 15 | |
| Depreciation | 18 | 21 | 18 | 21 | 22 | 23 | 22 | 22 | 23 | 23 | 22 | 28 | 29 | |
| Profit before tax | 14 | 17 | 22 | 24 | 28 | 28 | 29 | 26 | 31 | 21 | 54 | 22 | 34 | |
| Tax % | 20% | 20% | 17% | 23% | 23% | 24% | 28% | 26% | 24% | 22% | 20% | 26% | 25% | |
| Net Profit | 11 | 14 | 18 | 18 | 22 | 22 | 21 | 20 | 23 | 16 | 43 | 16 | 25 | |
| EPS in Rs | 3.60 | 4.21 | 5.70 | 5.63 | 6.80 | 6.69 | 6.53 | 6.03 | 7.16 | 5.08 | 13.37 | 4.88 | 7.81 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202627.11%Promoter
Promoters27.11%
FIIs3.84%0.44
DIIs14.50%
Public54.55%0.47
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹2,006.00 | 55.61 | 33,670 | 0.70% | 194 | +28.75% | 874 | +19.61% | 28.00% |
| Vijaya Diagnost. | ₹1,572.30 | 79.51 | 16,194 | 0.13% | 59 | +37.41% | 255 | +26.71% | 20.53% |
| Metropolis Healt | ₹566.00 | 50.89 | 11,746 | 0.35% | 75 | +43.04% | 497 | +15.76% | 17.81% |
| Thyrocare Tech. | ₹528.45 | 48.07 | 8,421 | 1.77% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹655.80 | 51.65 | 6,617 | 0.00% | 34 | +454.07% | 303 | +23.47% | 15.34% |
| Krsnaa Diagnost. | ₹519.05 | 16.67 | 1,684 | 0.39% | 25 | +8.95% | 240 | +31.17% | 12.71% |
| Suraksha Diagno. | ₹311.50 | 38.79 | 1,622 | 0.16% | 15 | +66.96% | 99 | +25.84% | 17.29% |
| Median: 16 Co. | ₹342.27 | 35.03 | 998 | 0.07% | 15 | +10.52% | 83 | +24.27% | 21.66% |
Filings
Annual reports6
Concall transcripts54
TranscriptNov 2026PPTNov 2026RECNov 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 7 Nov - Earnings Call Transcript for quarter and half year ended September 30, 2026Intimation Regarding Shifting Of Corporate Office Of Registrar And Share Transfer Agent Of The Company W.E.F. 1St December, 2026. 3 Nov - KFin Technologies shifts corporate office from December 1, 2026; registered office remains unchanged.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 3 Nov - Audio recording of Q2FY27 earnings call dated November 03, 2026 uploaded on company website.Submission Of Certificate Obtained From Statutory Auditors As per Regulation 169(5) Of The SEBI (Issue Of Capital And Disclosure Requirements) Regulations, 2018 (''ICDR Regulations'') 3 Nov - Submitted auditor certificate confirming ICDR Regulation 169(4) compliance.Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 3 Nov - Krsnaa Diagnostics wins Delhi MCD 10-year cash PPP project for CT Scan and MRI at three hospitals.



